ReShape Lifesciences Statistics Share Statistics ReShape Lifesciences has 2.39M
shares outstanding. The number of shares has increased by -0.19%
in one year.
Shares Outstanding 2.39M Shares Change (YoY) -0.19% Shares Change (QoQ) -0.17% Owned by Institutions (%) 0.04% Shares Floating 2.19M Failed to Deliver (FTD) Shares 2,952 FTD / Avg. Volume 0.11%
Short Selling Information The latest short interest is 185.34K, so 7.77% of the outstanding
shares have been sold short.
Short Interest 185.34K Short % of Shares Out 7.77% Short % of Float 7.77% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -8.06 and the forward
PE ratio is null.
ReShape Lifesciences's PEG ratio is
0.09.
PE Ratio -8.06 Forward PE n/a PS Ratio 7.18 Forward PS n/a PB Ratio -227.22 P/FCF Ratio -12.99 PEG Ratio 0.09
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ReShape Lifesciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.92,
with a Debt / Equity ratio of -3.82.
Current Ratio 0.92 Quick Ratio 0.43 Debt / Equity -3.82 Debt / EBITDA -0.15 Debt / FCF -0.22 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $470.94K Profits Per Employee $-419.41K Employee Count 17 Asset Turnover 1.67 Inventory Turnover 1.2
Taxes Income Tax 39K Effective Tax Rate -0.55%
Stock Price Statistics The stock price has increased by -99.28% in the
last 52 weeks. The beta is 1.9, so ReShape Lifesciences's
price volatility has been higher than the market average.
Beta 1.9 52-Week Price Change -99.28% 50-Day Moving Average 2.9 200-Day Moving Average 53.54 Relative Strength Index (RSI) 39.79 Average Volume (20 Days) 2,610,396
Income Statement In the last 12 months, ReShape Lifesciences had revenue of 8.01M
and earned -7.13M
in profits. Earnings per share was -13.83.
Revenue 8.01M Gross Profit 5.06M Operating Income -6.67M Net Income -7.13M EBITDA -6.67M EBIT -6.67M Earnings Per Share (EPS) -13.83
Full Income Statement Balance Sheet The company has 693K in cash and 967K in
debt, giving a net cash position of -274K.
Cash & Cash Equivalents 693K Total Debt 967K Net Cash -274K Retained Earnings -642.7M Total Assets 6.48M Working Capital 2.17M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4.43M
and capital expenditures 0, giving a free cash flow of -4.43M.
Operating Cash Flow -4.43M Capital Expenditures n/a Free Cash Flow -4.43M FCF Per Share -8.59
Full Cash Flow Statement Margins Gross margin is 63.17%, with operating and profit margins of -83.29% and -89.06%.
Gross Margin 63.17% Operating Margin -83.29% Pretax Margin -88.57% Profit Margin -89.06% EBITDA Margin -83.29% EBIT Margin -83.29% FCF Margin -55.3%
Dividends & Yields RSLS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for RSLS.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 9, 2025. It was a
backward
split with a ratio of 1:25.
Last Split Date May 9, 2025 Split Type backward Split Ratio 1:25
Scores Altman Z-Score -139.56 Piotroski F-Score 3
